FUTURE platform trial – A phase II platform trial of futibatinib in combination with (chemo)immunotherapy in colorectal cancer and other solid tumor entities

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517573-24-00

Acronym

FUTURE

Enrollment

Registered

2025-08-05

Start date

2025-12-08

Completion date

Unknown

Last updated

2025-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Brief summary

Objective response rate (ORR), defined as rate of patient who achieved complete or partial response (CR+PR) according to RECIST v1.1 as best response.

Detailed description

Duration of response (DoR), Progression free survival (PFS) according to RECIST v1.1, Overall survival (OS), Safety, Quality of life using EORTC QLQ-C30

Interventions

DRUGLytgobi 4 mg film-coated tablets

DRUGOxaliplatin Kabi 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUGLeucovorin 10 mg/ml Lösung zur Injektion/ Infusion

DRUG5-FU medac 50 mg/ml

DRUGInjektionslösung

DRUGTevimbra 100 mg concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Objective response rate (ORR), defined as rate of patient who achieved complete or partial response (CR+PR) according to RECIST v1.1 as best response.	—

Secondary

Measure	Time frame
Duration of response (DoR), Progression free survival (PFS) according to RECIST v1.1, Overall survival (OS), Safety, Quality of life using EORTC QLQ-C30	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026